

Table 9.1
Hodgkin Lymphoma

Trends in SEER Incidence^{ab} and U.S. Mortality^c Using the Joinpoint Regression Program,
1975-2013 With up to Five Joinpoints, 1992-2013 With up to Four Joinpoints,
Both Sexes by Race/Ethnicity

	JP Trend 1		JP Trend 2		JP Trend 3		JP Trend 4		JP Trend 5		JP Trend 6		AAPC ^d	
	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	2004-13	2009-13
<u>SEER 9 Delay-Adjusted Incidence^a, 1975-2013</u>														
All Races	1975-89	0.3	1989-01	-0.8*	2001-07	2.2*	2007-13	-2.6*					-1.0	-2.6*
White	1975-88	0.6*	1988-01	-0.9*	2001-07	2.2	2007-13	-2.8*					-1.2	-2.8*
Black	1975-13	1.1*											1.1*	1.1*
<u>SEER 13 Delay-Adjusted Incidence^b, 1992-2013</u>														
All Races	1992-01	-0.2	2001-07	1.6*	2007-13	-2.4*							-1.1*	-2.4*
White	1992-02	-0.2	2002-07	1.8	2007-13	-2.8*							-1.3*	-2.8*
Black	1992-13	0.8*											0.8*	0.8*
<u>SEER 9 Observed Incidence^a, 1975-2013</u>														
All Races	1975-89	0.3	1989-01	-0.8*	2001-07	2.2*	2007-13	-2.8*					-1.2*	-2.8*
White	1975-88	0.6*	1988-01	-0.9*	2001-07	2.1	2007-13	-3.1*					-1.4*	-3.1*
Black	1975-13	1.1*											1.1*	1.1*
<u>SEER 13 Observed Incidence^b, 1992-2013</u>														
All Races	1992-01	-0.2	2001-07	1.5*	2007-13	-2.7*							-1.3*	-2.7*
White	1992-02	-0.2	2002-07	1.8	2007-13	-3.0*							-1.5*	-3.0*
White NH ^{ef}	1992-08	0.6*	2008-13	-3.5*									-1.7*	-3.5*
Black	1992-13	0.8*											0.8*	0.8*
Black NH ^{ef}	1992-13	0.8*											0.8*	0.8*
API ^e	1992-96	-9.1	1996-01	11.6	2001-13	-0.2							-0.2	-0.2
AI/AN ^{eg}	-	-											-	-
Hispanic ^f	1992-13	0.0											0.0	0.0
<u>U.S. Cancer Mortality^c, 1975-2013</u>														
All Races	1975-79	-6.5*	1979-96	-3.5*	1996-13	-2.6*							-2.6*	-2.6*
White	1975-79	-6.2*	1979-95	-3.6*	1995-13	-2.6*							-2.6*	-2.6*
Black	1975-13	-2.9*											-2.9*	-2.9*
<u>U.S. Cancer Mortality^c, 1992-2013</u>														
All Races	1992-13	-2.8*											-2.8*	-2.8*
White	1992-13	-2.7*											-2.7*	-2.7*
White NH ^{ef}	1992-13	-2.7*											-2.7*	-2.7*
Black	1992-13	-2.9*											-2.9*	-2.9*
Black NH ^{ef}	1992-13	-2.7*											-2.7*	-2.7*
API ^e	1992-13	-2.1*											-2.1*	-2.1*
AI/AN ^{eg}	1992-13	-1.0											-1.0	-1.0
Hispanic ^f	1992-13	-2.4*											-2.4*	-2.4*

Joinpoint Regression Program Version 4.3.0.0, April 2016, National Cancer Institute. (<http://surveillance.cancer.gov/joinpoint/>).

The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

Trends are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Trends are from the SEER 13 areas (SEER 9 Areas, Los Angeles, San Jose-Monterey, Rural Georgia, and the Alaska Native Registry).

Trends are from US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint.

API - Asian/Pacific Islander, AI/AN - American Indian/Alaska Native, NH - Non-Hispanic

Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska

Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

The Hispanic and Non-Hispanic mortality trends exclude deaths from New Hampshire and Oklahoma.

Data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

* The APC/AAPC is significantly different from zero ($p < .05$).

- Joinpoint regression line analysis could not be performed on data series.

Table 9.2
Hodgkin Lymphoma

Trends in SEER Incidence^{ab} and U.S. Mortality^c Using the Joinpoint Regression Program,
1975-2013 With up to Five Joinpoints, 1992-2013 With up to Four Joinpoints,
Males by Race/Ethnicity

	JP Trend 1		JP Trend 2		JP Trend 3		JP Trend 4		JP Trend 5		JP Trend 6		AAPC ^d	
	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	2004-13	2009-13
<u>SEER 9 Delay-Adjusted Incidence^a, 1975-2013</u>														
All Races	1975-03	-0.7*	2003-07	3.4	2007-13	-2.5*							-0.6	-2.5*
White	1975-89	0.4	1989-92	-4.5	1992-13	0.0							0.0	0.0
Black	1975-13	0.6											0.6	0.6
<u>SEER 13 Delay-Adjusted Incidence^b, 1992-2013</u>														
All Races	1992-13	0.1											0.1	0.1
White	1992-13	0.0											0.0	0.0
Black	1992-13	1.1*											1.1*	1.1*
<u>SEER 9 Observed Incidence^a, 1975-2013</u>														
All Races	1975-03	-0.7*	2003-07	3.3	2007-13	-2.7*							-0.8	-2.7*
White	1975-04	-0.6*	2004-07	4.3	2007-13	-3.1*							-0.7	-3.1*
Black	1975-13	0.5											0.5	0.5
<u>SEER 13 Observed Incidence^b, 1992-2013</u>														
All Races	1992-07	0.5*	2007-13	-1.7*									-1.0*	-1.7*
White	1992-13	-0.1											-0.1	-0.1
White NH ^{ef}	1992-13	0.1											0.1	0.1
Black	1992-13	1.0*											1.0*	1.0*
Black NH ^{ef}	1992-13	1.0*											1.0*	1.0*
API ^e	1992-13	1.3											1.3	1.3
AI/AN ^{eg}	-	-											-	-
Hispanic ^f	1992-13	-0.5											-0.5	-0.5
<u>U.S. Cancer Mortality^c, 1975-2013</u>														
All Races	1975-96	-4.1*	1996-13	-2.5*									-2.5*	-2.5*
White	1975-96	-4.1*	1996-13	-2.4*									-2.4*	-2.4*
Black	1975-13	-3.2*											-3.2*	-3.2*
<u>U.S. Cancer Mortality^c, 1992-2013</u>														
All Races	1992-94	-10.4	1994-13	-2.4*									-2.4*	-2.4*
White	1992-94	-10.8	1994-13	-2.3*									-2.3*	-2.3*
White NH ^{ef}	1992-13	-2.6*											-2.6*	-2.6*
Black	1992-13	-3.3*											-3.3*	-3.3*
Black NH ^{ef}	1992-13	-3.1*											-3.1*	-3.1*
API ^e	1992-13	-2.7*											-2.7*	-2.7*
AI/AN ^{eg}	-	-											-	-
Hispanic ^f	1992-13	-2.4*											-2.4*	-2.4*

Joinpoint Regression Program Version 4.3.0.0, April 2016, National Cancer Institute. (<http://surveillance.cancer.gov/joinpoint/>).

The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

Trends are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Trends are from the SEER 13 areas (SEER 9 Areas, Los Angeles, San Jose-Monterey, Rural Georgia, and the Alaska Native Registry).

Trends are from US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint.

API - Asian/Pacific Islander, AI/AN - American Indian/Alaska Native, NH - Non-Hispanic

Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska

Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

The Hispanic and Non-Hispanic mortality trends exclude deaths from New Hampshire and Oklahoma.

Data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

* The APC/AAPC is significantly different from zero (p<.05).

- Joinpoint regression line analysis could not be performed on data series.

a
b
c
d
e
f
g
*
-

Table 9.3
Hodgkin Lymphoma

Trends in SEER Incidence^{ab} and U.S. Mortality^c Using the Joinpoint Regression Program,
1975-2013 With up to Five Joinpoints, 1992-2013 With up to Four Joinpoints,
Females by Race/Ethnicity

	JP Trend 1		JP Trend 2		JP Trend 3		JP Trend 4		JP Trend 5		JP Trend 6		AAPC ^d	
	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	2004-13	2009-13
<u>SEER 9 Delay-Adjusted Incidence^a, 1975-2013</u>														
All Races	1975-07	0.4*	2007-13	-2.2									-1.3	-2.2
White	1975-08	0.4*	2008-13	-3.1									-1.6	-3.1
Black	1975-13	1.8*											1.8*	1.8*
<u>SEER 13 Delay-Adjusted Incidence^b, 1992-2013</u>														
All Races	1992-13	-0.1											-0.1	-0.1
White	1992-09	0.3	2009-13	-4.2									-1.8	-4.2
Black	1992-13	0.5											0.5	0.5
<u>SEER 9 Observed Incidence^a, 1975-2013</u>														
All Races	1975-07	0.4*	2007-13	-2.4									-1.5	-2.4
White	1975-08	0.4*	2008-13	-3.5									-1.8	-3.5
Black	1975-13	1.8*											1.8*	1.8*
<u>SEER 13 Observed Incidence^b, 1992-2013</u>														
All Races	1992-13	-0.2											-0.2	-0.2
White	1992-09	0.2	2009-13	-4.6									-1.9	-4.6
White NH ^{ef}	1992-07	0.6	2007-13	-3.4*									-2.1*	-3.4*
Black	1992-13	0.4											0.4	0.4
Black NH ^{ef}	1992-13	0.5											0.5	0.5
API ^e	1992-13	2.3*											2.3*	2.3*
AI/AN ^{eg}	-	-											-	-
Hispanic ^f	1992-13	0.5											0.5	0.5
<u>U.S. Cancer Mortality^c, 1975-2013</u>														
All Races	1975-84	-4.9*	1984-13	-2.7*									-2.7*	-2.7*
White	1975-85	-4.9*	1985-13	-2.7*									-2.7*	-2.7*
Black	1975-13	-2.5*											-2.5*	-2.5*
<u>U.S. Cancer Mortality^c, 1992-2013</u>														
All Races	1992-13	-2.9*											-2.9*	-2.9*
White	1992-13	-2.8*											-2.8*	-2.8*
White NH ^{ef}	1992-13	-2.8*											-2.8*	-2.8*
Black	1992-13	-2.5*											-2.5*	-2.5*
Black NH ^{ef}	1992-13	-2.4*											-2.4*	-2.4*
API ^e	-	-											-	-
AI/AN ^{eg}	-	-											-	-
Hispanic ^f	1992-13	-2.4*											-2.4*	-2.4*

Joinpoint Regression Program Version 4.3.0.0, April 2016, National Cancer Institute. (<http://surveillance.cancer.gov/joinpoint/>).

The APC is the Annual Percent Change based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

Trends are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Trends are from the SEER 13 areas (SEER 9 Areas, Los Angeles, San Jose-Monterey, Rural Georgia, and the Alaska Native Registry).

Trends are from US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

The AAPC is the Average Annual Percent Change and is based on the APCs calculated by Joinpoint.

API - Asian/Pacific Islander, AI/AN - American Indian/Alaska Native, NH - Non-Hispanic

Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska

Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

The Hispanic and Non-Hispanic mortality trends exclude deaths from New Hampshire and Oklahoma.

Data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

* The APC/AAPC is significantly different from zero ($p < .05$).

- Joinpoint regression line analysis could not be performed on data series.

Table 9.4
Hodgkin Lymphoma

Delay-adjusted SEER Incidence^a Rates by Year, Race and Sex

Year of Diagnosis:	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
1975	3.09	3.86	2.40	3.23	3.91	2.64	2.58	4.41	1.10
1976	2.76	3.37	2.24	2.88	3.45	2.41	2.57	3.91	1.39
1977	2.98	3.61	2.46	3.27	3.93	2.71	1.68	1.91	1.39
1978	2.80	3.41	2.32	3.07	3.70	2.58	1.47	2.01	1.02
1979	2.93	3.91	2.08	3.09	4.05	2.27	2.86	4.68	1.41
1980	2.77	3.31	2.27	2.98	3.53	2.48	1.82	2.07	1.54
1981	2.92	3.59	2.34	3.23	3.92	2.62	1.43	1.94	0.98
1982	2.92	3.50	2.45	3.13	3.67	2.69	2.58	3.15	2.04
1983	3.03	3.73	2.39	3.34	4.01	2.70	2.11	3.85	0.96
1984	3.06	3.72	2.47	3.38	4.01	2.79	2.07	3.31	1.12
1985	2.98	3.50	2.51	3.31	3.84	2.83	1.74	2.26	1.27
1986	2.73	3.33	2.22	2.91	3.50	2.41	2.27	2.80	1.90
1987	3.04	3.71	2.50	3.34	4.00	2.78	2.12	2.78	1.54
1988	3.10	3.59	2.67	3.43	4.00	2.94	1.94	1.93	1.93
1989	3.06	3.68	2.54	3.35	3.97	2.84	2.16	3.15	1.37
1990	3.07	3.51	2.64	3.30	3.82	2.79	3.02	3.23	2.81
1991	3.02	3.49	2.60	3.34	3.83	2.90	2.40	2.70	2.08
1992	2.87	3.11	2.69	3.05	3.23	2.92	2.66	2.71	2.61
1993	2.86	3.27	2.50	3.09	3.49	2.75	2.96	3.64	2.46
1994	2.85	3.15	2.59	3.14	3.49	2.82	2.15	2.41	1.99
1995	2.76	3.22	2.36	3.05	3.51	2.65	2.32	2.93	1.78
1996	2.85	3.32	2.41	3.14	3.63	2.68	2.46	3.19	1.83
1997	2.82	2.95	2.70	3.07	3.22	2.92	2.57	2.38	2.72
1998	2.79	3.11	2.53	3.13	3.45	2.87	2.15	2.46	1.89
1999	2.86	3.08	2.69	3.10	3.23	3.03	2.52	3.14	2.01
2000	2.82	3.30	2.37	3.06	3.54	2.62	2.42	3.03	1.87
2001	2.57	2.95	2.23	2.73	3.12	2.37	2.48	3.17	1.98
2002	2.95	3.27	2.70	3.15	3.44	2.91	2.95	3.23	2.77
2003	2.72	3.12	2.37	3.02	3.47	2.61	2.40	2.76	2.23
2004	2.94	3.05	2.88	3.11	3.19	3.08	3.17	3.25	3.13
2005	3.02	3.52	2.61	3.25	3.75	2.84	3.19	3.49	2.91
2006	3.00	3.32	2.70	3.22	3.50	2.92	3.17	3.94	2.51
2007	3.19	3.68	2.75	3.46	3.91	3.04	3.35	4.11	2.69
2008	2.96	3.38	2.58	3.21	3.61	2.86	3.06	3.63	2.56
2009	2.94	3.20	2.72	3.24	3.49	3.02	2.65	3.24	2.13
2010	2.81	3.27	2.39	3.04	3.54	2.57	2.53	3.04	2.09
2011	2.76	3.19	2.35	2.94	3.38	2.53	2.92	3.49	2.39
2012	2.74	3.06	2.45	2.95	3.29	2.62	2.84	2.89	2.75
2013	2.71	3.12	2.35	2.86	3.21	2.57	2.91	3.64	2.29

Additional information on the model used to delay-adjust SEER Incidence rates can be found at [\(http://surveillance.cancer.gov/delay/\)](http://surveillance.cancer.gov/delay/).

^a SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta). Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

- Delay-adjusted rate is not shown for observed rates based on less than 16 cases for the time interval.

Table 9.5
Hodgkin Lymphoma

Age-adjusted SEER Incidence^a Rates by Year, Race and Sex

Year of Diagnosis:	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
1975-2013	2.89	3.34	2.50	3.14	3.59	2.74	2.54	3.10	2.08
1975	3.09	3.86	2.40	3.23	3.91	2.64	2.58	4.41	-
1976	2.76	3.37	2.24	2.88	3.45	2.41	2.57	3.91	-
1977	2.98	3.61	2.46	3.27	3.93	2.71	1.68	1.91	-
1978	2.80	3.41	2.32	3.07	3.70	2.58	1.47	2.01	-
1979	2.93	3.91	2.08	3.09	4.05	2.27	2.86	4.68	-
1980	2.77	3.31	2.27	2.98	3.53	2.48	1.82	2.07	1.54
1981	2.92	3.59	2.34	3.23	3.92	2.62	1.43	1.94	-
1982	2.92	3.50	2.45	3.13	3.67	2.69	2.58	3.15	2.04
1983	3.03	3.73	2.39	3.34	4.01	2.70	2.11	3.85	-
1984	3.06	3.72	2.47	3.38	4.01	2.79	2.07	3.31	-
1985	2.98	3.50	2.51	3.31	3.84	2.83	1.74	2.26	-
1986	2.73	3.33	2.22	2.91	3.50	2.41	2.27	2.80	1.90
1987	3.04	3.71	2.50	3.34	4.00	2.78	2.12	2.78	1.54
1988	3.10	3.59	2.67	3.43	4.00	2.94	1.94	1.93	1.93
1989	3.06	3.68	2.54	3.35	3.97	2.84	2.16	3.15	1.37
1990	3.07	3.51	2.64	3.30	3.82	2.79	3.02	3.23	2.81
1991	3.02	3.49	2.60	3.34	3.83	2.90	2.40	2.70	2.08
1992	2.87	3.11	2.69	3.05	3.23	2.92	2.66	2.71	2.61
1993	2.86	3.27	2.50	3.09	3.49	2.75	2.96	3.64	2.46
1994	2.85	3.15	2.59	3.14	3.49	2.82	2.15	2.41	1.99
1995	2.76	3.22	2.36	3.05	3.51	2.65	2.32	2.93	1.78
1996	2.85	3.32	2.41	3.14	3.63	2.68	2.46	3.19	1.83
1997	2.82	2.95	2.70	3.07	3.22	2.92	2.57	2.38	2.72
1998	2.79	3.11	2.53	3.13	3.45	2.87	2.15	2.46	1.89
1999	2.86	3.08	2.69	3.10	3.23	3.03	2.52	3.14	2.01
2000	2.82	3.30	2.37	3.06	3.54	2.62	2.42	3.03	1.87
2001	2.57	2.95	2.23	2.73	3.12	2.37	2.48	3.17	1.98
2002	2.95	3.27	2.70	3.15	3.44	2.91	2.95	3.23	2.77
2003	2.72	3.12	2.37	3.02	3.47	2.61	2.40	2.76	2.23
2004	2.94	3.05	2.88	3.11	3.19	3.08	3.17	3.25	3.13
2005	3.02	3.52	2.61	3.24	3.74	2.83	3.18	3.49	2.90
2006	3.00	3.31	2.69	3.21	3.49	2.91	3.16	3.93	2.51
2007	3.18	3.67	2.74	3.45	3.90	3.03	3.33	4.10	2.68
2008	2.94	3.36	2.57	3.19	3.59	2.84	3.04	3.61	2.55
2009	2.93	3.19	2.70	3.22	3.47	3.00	2.63	3.21	2.12
2010	2.79	3.25	2.37	3.01	3.51	2.54	2.51	3.02	2.08
2011	2.73	3.17	2.33	2.91	3.35	2.50	2.89	3.46	2.37
2012	2.71	3.02	2.42	2.90	3.24	2.58	2.80	2.85	2.72
2013	2.66	3.06	2.31	2.80	3.14	2.51	2.84	3.56	2.23

^a SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta). Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 9.6
Hodgkin Lymphoma

Age-adjusted U.S. Death^a Rates by Year, Race and Sex

Year of Death:	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
1975-2013	0.61	0.77	0.48	0.64	0.80	0.51	0.52	0.69	0.38
1975	1.31	1.69	1.00	1.35	1.73	1.04	1.07	1.50	0.72
1976	1.17	1.50	0.90	1.20	1.52	0.94	0.97	1.44	0.60
1977	1.14	1.45	0.87	1.18	1.49	0.90	0.92	1.20	0.69
1978	1.06	1.35	0.82	1.10	1.38	0.87	0.76	1.17	0.44
1979	0.97	1.27	0.71	1.00	1.31	0.74	0.76	1.06	0.51
1980	0.98	1.23	0.76	1.01	1.27	0.80	0.75	1.09	0.48
1981	0.93	1.15	0.74	0.96	1.19	0.76	0.74	0.88	0.62
1982	0.88	1.09	0.70	0.92	1.15	0.72	0.70	0.78	0.62
1983	0.85	1.09	0.65	0.88	1.13	0.68	0.64	0.90	0.45
1984	0.86	1.18	0.60	0.88	1.19	0.63	0.79	1.18	0.47
1985	0.77	0.98	0.58	0.78	1.00	0.60	0.71	0.96	0.51
1986	0.78	1.00	0.58	0.80	1.04	0.60	0.65	0.85	0.49
1987	0.74	0.96	0.56	0.77	0.98	0.58	0.67	0.94	0.46
1988	0.67	0.88	0.50	0.69	0.91	0.51	0.59	0.75	0.48
1989	0.71	0.92	0.54	0.73	0.94	0.56	0.66	0.92	0.47
1990	0.66	0.85	0.50	0.69	0.88	0.52	0.56	0.81	0.36
1991	0.65	0.83	0.51	0.66	0.83	0.51	0.67	0.89	0.49
1992	0.65	0.83	0.50	0.67	0.86	0.52	0.58	0.77	0.45
1993	0.61	0.79	0.47	0.63	0.80	0.50	0.57	0.83	0.39
1994	0.56	0.66	0.47	0.56	0.66	0.48	0.55	0.73	0.41
1995	0.55	0.67	0.44	0.56	0.68	0.46	0.53	0.73	0.36
1996	0.53	0.64	0.44	0.55	0.65	0.46	0.47	0.63	0.36
1997	0.53	0.62	0.46	0.54	0.63	0.47	0.54	0.67	0.43
1998	0.48	0.61	0.36	0.49	0.62	0.37	0.48	0.66	0.33
1999	0.51	0.63	0.41	0.53	0.66	0.43	0.41	0.55	0.30
2000	0.46	0.55	0.39	0.48	0.57	0.41	0.35	0.42	0.30
2001	0.47	0.56	0.38	0.48	0.59	0.39	0.42	0.52	0.35
2002	0.47	0.58	0.38	0.49	0.60	0.41	0.40	0.57	0.27
2003	0.46	0.55	0.39	0.48	0.57	0.41	0.36	0.47	0.27
2004	0.43	0.55	0.34	0.44	0.57	0.35	0.40	0.47	0.34
2005	0.42	0.51	0.36	0.43	0.51	0.37	0.42	0.55	0.32
2006	0.44	0.56	0.33	0.45	0.57	0.35	0.41	0.56	0.30
2007	0.41	0.51	0.33	0.43	0.53	0.35	0.36	0.45	0.29
2008	0.37	0.45	0.31	0.39	0.47	0.33	0.33	0.39	0.28
2009	0.40	0.48	0.32	0.41	0.49	0.34	0.39	0.48	0.30
2010	0.38	0.49	0.29	0.40	0.51	0.31	0.30	0.36	0.26
2011	0.36	0.47	0.27	0.37	0.48	0.28	0.35	0.50	0.24
2012	0.34	0.42	0.27	0.35	0.43	0.28	0.33	0.41	0.26
2013	0.32	0.40	0.25	0.34	0.42	0.26	0.28	0.34	0.24

^a US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 9.7
Hodgkin LymphomaSEER Incidence^a and U.S. Death^b Rates, Age-Adjusted and Age-Specific Rates, by Race and Sex

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>SEER Incidence</u>									
<u>Age at Diagnosis</u>									
Age-Adjusted Rates, 2009-2013									
All ages	2.6	3.0	2.3	2.8	3.1	2.5	2.6	3.0	2.2
Under 65	2.4	2.7	2.2	2.6	2.8	2.4	2.6	3.1	2.2
65 and over	3.8	4.8	3.1	4.2	5.3	3.3	2.5	2.7	2.3
All ages (IARC world std) ^c	2.4	2.6	2.1	2.5	2.7	2.3	2.4	2.7	2.1
Age-Specific Rates, 2009-2013									
<1	-	-	-	-	-	-	-	-	-
1-4	0.1	0.2	-	0.1	-	-	-	-	-
5-9	0.4	0.7	0.2	0.4	0.6	0.2	0.6	0.8	-
10-14	1.2	1.3	1.0	1.2	1.4	1.0	1.1	1.0	1.2
15-19	3.0	3.0	3.1	3.4	3.3	3.5	2.2	2.2	2.2
20-24	4.3	4.1	4.5	4.6	4.4	4.9	3.5	3.4	3.5
25-29	3.9	3.9	3.9	4.2	4.1	4.3	4.0	4.3	3.7
30-34	3.6	3.7	3.4	3.9	4.0	3.7	3.6	4.1	3.2
35-39	2.7	3.0	2.5	2.9	3.1	2.6	3.4	3.9	2.9
40-44	2.7	3.3	2.2	2.8	3.3	2.3	3.7	5.0	2.4
45-49	2.4	3.0	1.8	2.5	3.0	1.9	3.4	4.6	2.3
50-54	2.3	3.0	1.7	2.4	3.0	1.8	3.2	4.4	2.1
55-59	2.5	3.2	2.0	2.7	3.3	2.0	2.7	3.2	2.2
60-64	2.6	2.9	2.3	2.8	3.1	2.4	3.3	3.0	3.5
65-69	3.2	3.9	2.5	3.4	4.1	2.8	3.1	3.1	3.0
70-74	3.9	4.9	3.1	4.2	5.3	3.3	2.9	3.9	-
75-79	4.5	5.5	3.7	4.9	6.1	4.0	-	-	-
80-84	4.2	5.3	3.4	4.4	5.5	3.7	-	-	-
85+	3.7	5.2	3.0	4.0	5.9	3.0	-	-	-
<u>U.S. Mortality</u>									
<u>Age at Death</u>									
Age-Adjusted Rates, 2009-2013									
All ages	0.4	0.5	0.3	0.4	0.5	0.3	0.3	0.4	0.3
Under 65	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.2
65 and over	1.5	1.9	1.2	1.6	2.0	1.2	0.9	1.2	0.8
All ages (IARC world std) ^c	0.2	0.3	0.2	0.3	0.3	0.2	0.2	0.3	0.2
Age-Specific Rates, 2009-2013									
<1	-	-	-	-	-	-	-	-	-
1-4	-	-	-	-	-	-	-	-	-
5-9	-	-	-	-	-	-	-	-	-
10-14	-	-	-	-	-	-	-	-	-
15-19	0.1	0.1	0.0	0.1	0.1	0.0	-	-	-
20-24	0.2	0.2	0.1	0.2	0.2	0.1	0.2	-	0.2
25-29	0.2	0.3	0.2	0.2	0.3	0.2	0.3	0.4	0.3
30-34	0.3	0.3	0.2	0.3	0.3	0.2	0.4	0.4	0.3
35-39	0.3	0.3	0.2	0.3	0.3	0.2	0.4	0.5	0.3
40-44	0.3	0.3	0.2	0.3	0.3	0.2	0.2	0.3	-
45-49	0.3	0.3	0.2	0.3	0.3	0.2	0.4	0.5	0.2
50-54	0.3	0.4	0.2	0.3	0.4	0.2	0.4	0.6	-
55-59	0.4	0.5	0.3	0.4	0.5	0.3	0.5	0.6	0.5
60-64	0.5	0.7	0.4	0.6	0.7	0.5	0.5	0.8	0.3
65-69	0.8	1.1	0.6	0.9	1.1	0.6	0.7	1.1	-
70-74	1.2	1.5	0.9	1.3	1.7	0.9	0.7	0.8	0.7
75-79	1.6	1.9	1.3	1.7	2.0	1.5	0.8	1.4	-
80-84	2.3	2.9	1.9	2.5	3.1	2.0	1.1	-	1.3
85+	2.3	3.2	1.9	2.4	3.4	1.9	1.6	-	1.5

^a SEER 18 areas. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130), unless noted.

^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

^c Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130), unless noted.

- Rates are per 100,000 and are age-adjusted to the IARC world standard population.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 9.8
Hodgkin Lymphoma

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	40	34	48	-	-	-
1970-1973 ^a	-	-	-	67	66	69	-	-	-
1975-1977 ^b	71.8	69.9	74.3	72.1	70.2	74.5	70.1	68.5 ^g	73.3 ^g
1978-1980 ^b	71.7	70.3	73.5	71.8	69.8	74.3	70.6	74.7 ^g	63.1 ^g
1981-1983 ^b	74.2	73.0	75.8	74.6	73.8	75.6	71.8	69.6 ^g	75.9 ^g
1984-1986 ^b	78.3	76.5	80.6	78.8	76.9	81.2	74.7	75.7 ^g	72.1 ^g
1987-1989 ^b	79.2	76.6	82.5	79.7	76.8	83.3	72.3	70.9 ^g	74.0 ^g
1990-1992 ^b	81.7	79.2	84.7	82.8	81.0	84.9	74.2	64.9	84.3
1993-1995 ^b	81.7	79.2	84.6	82.2	80.0	84.7	78.3	74.0	83.0
1996-1998 ^b	85.1	84.4	85.9	85.7	84.4	87.3	81.1	84.3	77.7
1999-2001 ^b	85.1	82.8	87.9	85.7	84.0	87.8	81.4	75.3	89.6
2002-2005 ^b	86.8	85.9	87.7	87.9	87.3	88.6	81.3	76.6	85.4
2006-2012 ^b	88.5 ^f	87.3 ^f	89.8 ^f	89.0 ^f	88.6 ^f	89.5 ^f	85.6 ^f	80.8 ^f	91.4 ^f
5-Year Period Survival (Percent) ^{cd}									
2012	86.5	85.6	87.6	86.6	86.2	87.1	83.9	79.0	89.4
Stage Distribution (%) 2006-2012 ^{ce}									
All Stages									
Number of cases	14,954	8,168	6,786	12,094	6,624	5,470	1,867	1,009	858
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	16	17	15	16	17	15	19	19	18
Regional	40	35	46	41	36	47	32	26	39
Distant	39	43	34	38	42	33	47	53	40
Unstaged	4	4	5	4	4	5	3	2	3
5-Year Relative Survival (Percent), 2006-2012 ^c									
Age at Diagnosis:									
Ages <45	94.3	93.2	95.5	95.1	94.5	95.8	88.6	84.5	93.4
Ages 45-54	86.9	84.8	90.0	88.4	87.1	90.4	78.7	71.8	88.9
Ages 55-64	78.1	78.3	77.8	79.3	80.5	77.5	65.7	56.6 ^g	74.1 ^g
Ages 65-74	64.6	62.6	67.1	64.3	61.1	68.2	69.8 ^g	82.5 ^g	53.5 ^g
Ages 75+	41.9	42.2	41.3	42.4	41.7	42.1	45.5 ^h	-	37.5 ^h
Ages <65	91.3	90.0	92.9	92.2	91.5	93.1	84.7	79.7	90.7
Ages 65+	54.3	54.3	54.2	54.0	52.7	54.9	63.4 ^g	80.8 ^g	48.3 ^g
Stage ^e :									
All Stages	86.2	85.4	87.3	86.5	86.0	87.0	83.3	79.8	87.3
Localized	91.5	92.8	89.5	91.5	93.0	89.2	90.2	90.2	89.9
Regional	93.1	92.5	93.7	93.5	93.0	93.9	90.2	88.4	91.4
Distant	77.3	77.1	77.7	77.2	77.8	76.3	75.9	71.4	82.4
Unstaged	81.9	79.7	84.2	81.6	79.2	84.1	73.6 ^g	74.8 ^h	-

^a Based on End Results data from a series of hospital registries and one population-based registry.^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2013.

^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Based on follow-up of patients into 2013.

^d Period survival provides a 2012 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.^f The difference between 1975-1977 and 2006-2012 is statistically significant (p<.05).^g The standard error is between 5 and 10 percentage points.^h The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.

Table 9.9
Hodgkin Lymphoma

SEER^a Relative Survival (Percent)
By Year of Diagnosis

All Races, Males and Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	86.9	89.4	90.7	92.0	92.8	91.5	93.6	94.6	91.0	92.4	94.0	92.8	93.2	91.5	93.4	92.5	93.3	94.7	92.2	91.7	93.6	94.5
2-year	80.8	83.6	86.3	87.7	88.6	88.1	90.9	90.5	87.7	90.6	90.8	89.8	92.2	89.6	90.9	90.2	92.5	92.7	89.6	90.4	92.2	
3-year	76.5	80.0	82.9	85.1	86.5	86.7	89.3	88.3	85.4	88.7	88.5	88.4	89.9	87.4	90.3	89.0	90.7	91.6	88.1	89.4		
4-year	73.7	77.4	80.5	83.2	83.4	84.6	88.4	86.6	84.2	87.9	86.6	86.1	88.1	86.1	89.4	88.6	89.0	90.6	87.0			
5-year	71.4	74.8	79.0	81.6	82.2	83.2	87.2	84.9	83.4	86.4	85.2	85.1	87.5	86.0	88.3	88.3	88.4	90.4				
6-year	69.0	72.3	77.4	80.0	80.1	81.7	85.9	83.7	82.2	85.6	84.3	84.7	87.0	84.9	87.9	87.0	86.8					
7-year	67.1	70.6	75.1	78.6	78.9	80.0	85.2	83.0	80.9	84.8	84.3	83.3	86.3	84.3	87.2	86.3						
8-year	65.0	69.2	74.0	77.7	78.4	79.3	84.7	82.4	80.0	83.8	83.8	82.4	85.6	83.4	85.6							
9-year	63.0	67.8	73.2	76.8	77.2	78.2	84.4	81.4	79.0	82.9	82.8	81.3	84.7	82.9								
10-year	61.7	66.7	72.6	76.0	76.6	76.7	83.8	80.2	78.1	82.9	81.8	80.5	84.3									
11-year	60.4	65.7	71.6	75.4	75.6	75.7	83.3	79.5	78.0	82.8	81.3	78.9										
12-year	59.4	64.6	70.8	74.6	75.5	74.8	82.8	79.2	77.5	82.3	81.1											
13-year	58.7	63.7	69.6	73.9	75.4	74.2	81.7	78.9	76.3	81.9												
14-year	57.4	62.6	68.5	73.5	75.4	73.5	80.0	78.3	76.2													
15-year	56.4	61.7	67.4	72.9	75.3	73.1	79.2	77.0														
16-year	55.6	60.7	66.7	72.4	75.0	73.1	78.8															
17-year	54.7	59.3	66.1	71.8	74.6	72.3																
18-year	53.7	58.5	65.5	71.1	73.7																	
19-year	53.1	57.8	64.8	70.2																		
20-year	52.1	56.8	64.0																			

^a Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 9.10
Hodgkin Lymphoma

SEER^a Relative Survival (Percent)
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	85.9	89.4	89.8	91.2	92.2	92.7	92.1	94.3	89.3	90.8	92.9	90.8	93.0	89.7	93.3	91.7	92.4	93.4	93.0	90.2	92.6	93.6
2-year	80.2	83.6	84.7	85.8	88.0	88.6	89.5	91.0	86.1	88.4	89.1	88.2	92.2	88.4	90.7	89.2	91.6	91.4	89.4	89.4	91.5	
3-year	75.3	80.3	81.3	83.0	85.1	87.1	87.4	88.8	83.6	85.4	86.6	86.7	89.9	86.4	90.0	88.7	89.4	90.5	87.7	87.6		
4-year	71.7	77.2	78.3	80.8	81.0	85.1	86.9	86.5	82.8	83.7	85.1	84.8	86.8	85.9	88.7	87.6	87.6	89.1	86.9			
5-year	69.2	74.1	76.4	79.0	80.2	83.0	85.8	84.5	82.5	81.8	83.7	83.7	86.1	85.9	87.6	87.4	86.9	89.1				
6-year	66.5	71.4	74.6	77.1	78.8	81.9	83.5	83.5	80.5	80.9	82.1	83.0	86.1	83.9	86.8	85.7	84.9					
7-year	64.4	69.7	71.8	76.0	77.6	79.7	82.9	82.3	78.7	80.2	81.8	81.1	85.1	83.7	85.7	85.4						
8-year	62.4	68.2	70.4	74.8	76.5	78.6	82.2	81.8	77.5	79.1	81.4	79.9	84.2	82.7	83.0							
9-year	60.0	67.0	69.2	73.8	75.3	77.6	82.2	80.3	76.1	78.8	79.6	79.1	82.7	82.7								
10-year	58.9	65.7	68.6	73.2	75.3	75.3	81.0	78.3	75.1	78.7	78.2	78.4	82.1									
11-year	57.5	64.7	67.1	72.6	74.3	74.1	80.4	77.6	75.1	77.9	77.3	75.8										
12-year	56.4	63.3	66.0	71.9	74.2	72.6	80.3	77.2	74.1	77.2	77.0											
13-year	55.7	62.6	64.4	71.0	74.2	72.0	78.5	77.0	71.6	76.6												
14-year	54.4	61.2	63.2	70.6	74.2	70.6	76.8	76.0	71.4													
15-year	53.1	60.5	62.0	69.9	74.2	70.0	75.8	73.1														
16-year	52.4	59.5	61.1	69.5	74.2	70.0	75.4															
17-year	51.1	58.1	60.7	68.8	74.2	69.6																
18-year	50.2	57.0	60.0	68.0	73.0																	
19-year	49.5	56.6	59.4	67.3																		
20-year	48.6	55.2	58.4																			

^a Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 9.11
Hodgkin Lymphoma

SEER^a Relative Survival (Percent)
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	88.2	89.5	91.8	93.0	93.7	90.0	95.1	94.9	92.9	94.5	95.3	95.2	93.4	93.3	93.4	93.4	94.5	96.1	91.3	93.4	94.7	95.6
2-year	81.6	83.7	88.3	89.9	89.3	87.4	92.3	89.8	89.4	93.6	92.7	91.6	92.2	90.9	91.1	91.3	93.4	94.1	89.6	91.8	93.1	
3-year	78.1	79.7	85.0	87.6	88.1	86.2	91.3	87.6	87.5	93.1	90.8	90.2	90.0	88.3	90.6	89.4	92.4	92.9	88.4	91.4		
4-year	76.2	77.6	83.2	86.0	86.5	83.9	89.8	86.5	85.7	93.1	88.5	87.5	89.6	86.2	90.4	89.4	90.7	92.4	87.0			
5-year	74.4	75.7	82.1	84.7	84.6	83.5	88.5	85.3	84.4	92.5	87.1	86.7	89.1	86.1	89.2	89.3	90.2	91.6				
6-year	72.3	73.4	81.0	83.4	81.8	81.4	88.5	84.0	83.9	92.0	86.8	86.5	88.1	85.7	89.1	88.4	89.2					
7-year	70.8	71.8	79.2	81.7	80.6	80.4	87.7	83.6	83.2	91.1	86.8	85.7	87.8	84.9	89.0	87.3						
8-year	68.5	70.6	78.4	81.2	80.6	80.1	87.2	83.1	82.6	90.4	86.8	84.9	87.2	83.9	88.9							
9-year	66.9	68.9	78.1	80.3	79.4	78.9	86.6	82.6	82.2	88.5	86.7	83.5	87.0	83.0								
10-year	65.4	68.1	77.6	79.3	78.2	78.4	86.5	82.2	81.3	88.5	86.5	82.7	86.9									
11-year	64.2	67.1	77.2	78.8	77.4	77.5	86.1	81.7	80.8	88.5	86.4	82.3										
12-year	63.5	66.3	76.8	77.9	76.9	77.4	85.1	81.2	80.8	88.5	86.4											
13-year	62.5	65.2	76.1	77.5	76.1	77.1	84.9	80.8	80.8	88.5												
14-year	61.5	64.3	75.1	77.0	76.1	76.8	83.3	80.8	80.8													
15-year	60.7	63.3	74.0	76.5	75.9	76.8	82.6	80.8														
16-year	59.9	62.3	73.5	75.9	75.7	76.8	82.1															
17-year	59.4	61.0	72.8	75.4	75.1	75.7																
18-year	58.5	60.3	72.4	74.8	74.3																	
19-year	57.8	59.5	71.5	73.6																		
20-year	56.8	58.8	71.0																			

^a Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 9.12
Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10, 20 and 30 Years,
Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age, and
Lifetime Risk of Dying from Cancer Given Alive at Current Age
Both Sexes, 2011-2013 By Race/Ethnicity

Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer					Risk of Dying from Cancer	Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer					Risk of Dying from Cancer
		+10 yrs	+20 yrs	+30 yrs	Ever	+10 yrs				+20 yrs	+30 yrs	Ever			
All Races	0	0.00	0.02	0.06	0.21	0.04	Asian/ Pacific Islander	0	0.00	0.02	0.04	0.11	0.03		
	10	0.02	0.06	0.09	0.21	0.04		10	0.01	0.04	0.05	0.11	0.03		
	20	0.04	0.07	0.10	0.19	0.04		20	0.03	0.04	0.05	0.10	0.03		
	30	0.03	0.06	0.08	0.15	0.03		30	0.01	0.02	0.03	0.07	0.02		
	40	0.03	0.05	0.07	0.12	0.03		40	0.01	0.02	0.03	0.06	0.02		
	50	0.02	0.05	0.08	0.10	0.03		50	0.01	0.02	0.03	0.05	0.02		
	60	0.03	0.06	0.08	0.08	0.03		60	0.01	0.03	0.04	0.04	0.02		
	70	0.03	0.06	-	0.06	0.03		70	0.02	0.03	-	0.04	0.02		
80	0.03	-	-	0.04	0.02	80	0.02	-	-	0.02	0.02				
White	0	0.00	0.02	0.07	0.22	0.04	American Indian/ Alaska Native ^a	0	0.00	0.01	0.01	0.13	0.02		
	10	0.02	0.07	0.10	0.22	0.04		10	0.01	0.01	0.02	0.13	0.02		
	20	0.04	0.08	0.10	0.20	0.04		20	0.01	0.02	0.03	0.13	0.02		
	30	0.03	0.06	0.08	0.16	0.04		30	0.01	0.02	0.04	0.12	0.02		
	40	0.03	0.05	0.07	0.13	0.03		40	0.01	0.03	0.05	0.12	0.02		
	50	0.02	0.05	0.08	0.10	0.03		50	0.02	0.04	0.07	0.11	0.02		
	60	0.03	0.06	0.08	0.08	0.03		60	0.02	0.06	0.10	0.10	0.02		
	70	0.04	0.06	-	0.07	0.03		70	0.04	0.08	-	0.09	0.02		
80	0.03	-	-	0.04	0.02	80	0.06	-	-	0.07	0.02				
Black	0	0.00	0.02	0.05	0.19	0.03	Hispanic ^b	0	0.00	0.02	0.04	0.20	0.05		
	10	0.02	0.05	0.09	0.19	0.03		10	0.02	0.04	0.06	0.20	0.05		
	20	0.03	0.07	0.10	0.18	0.03		20	0.03	0.04	0.06	0.18	0.05		
	30	0.04	0.07	0.10	0.14	0.03		30	0.02	0.04	0.06	0.16	0.05		
	40	0.03	0.06	0.09	0.11	0.02		40	0.02	0.04	0.07	0.14	0.05		
	50	0.03	0.05	0.07	0.08	0.02		50	0.02	0.05	0.09	0.12	0.05		
	60	0.03	0.05	0.06	0.06	0.02		60	0.03	0.07	0.10	0.11	0.05		
	70	0.02	0.03	-	0.04	0.01		70	0.05	0.08	-	0.08	0.04		
80	0.02	-	-	0.02	0.01	80	0.04	-	-	0.05	0.03				

Devcan 6.7.4, August 2016, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: Incidence data are from the SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG). Mortality data are from the NCHS public use data file for the total US.

^a Underlying incidence and mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

- Statistic could not be calculated.

A percent of 0.00 represents a value that is below 0.005.

Table 9.13
Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10, 20 and 30 Years,
Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age, and
Lifetime Risk of Dying from Cancer Given Alive at Current Age
Males, 2011-2013 By Race/Ethnicity

Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer	Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer				Risk of Dying from Cancer
		+10 yrs	+20 yrs	+30 yrs	Ever				+10 yrs	+20 yrs	+30 yrs	Ever	
All Races	0	0.00	0.03	0.06	0.23	0.04	Asian/ Pacific Islander	0	0.01	0.02	0.05	0.13	0.03
	10	0.02	0.06	0.09	0.23	0.04		10	0.01	0.04	0.06	0.13	0.03
	20	0.04	0.07	0.10	0.21	0.04		20	0.03	0.04	0.05	0.11	0.03
	30	0.03	0.06	0.09	0.17	0.04		30	0.01	0.02	0.03	0.08	0.03
	40	0.03	0.06	0.09	0.14	0.04		40	0.01	0.02	0.03	0.07	0.03
	50	0.03	0.06	0.09	0.11	0.04		50	0.01	0.03	0.04	0.06	0.03
	60	0.03	0.06	0.09	0.09	0.04		60	0.01	0.03	0.05	0.05	0.03
	70	0.04	0.07	-	0.07	0.03		70	0.02	0.04	-	0.04	0.02
80	0.04	-	-	0.04	0.02	80	0.02	-	-	0.03	0.02		
White	0	0.00	0.03	0.07	0.24	0.04	American Indian/ Alaska Native ^a	0	0.00	0.01	0.01	0.18	0.03
	10	0.02	0.06	0.10	0.24	0.04		10	0.00	0.01	0.03	0.18	0.03
	20	0.04	0.08	0.11	0.22	0.04		20	0.01	0.03	0.04	0.17	0.03
	30	0.04	0.07	0.09	0.18	0.04		30	0.02	0.04	0.05	0.17	0.03
	40	0.03	0.06	0.09	0.15	0.04		40	0.02	0.03	0.07	0.16	0.03
	50	0.03	0.06	0.09	0.12	0.04		50	0.01	0.05	0.10	0.14	0.03
	60	0.03	0.07	0.09	0.10	0.04		60	0.05	0.09	0.14	0.15	0.03
	70	0.04	0.07	-	0.08	0.03		70	0.06	0.11	-	0.12	0.03
80	0.04	-	-	0.05	0.03	80	0.08	-	-	0.09	0.05		
Black	0	0.01	0.02	0.06	0.21	0.03	Hispanic ^b	0	0.00	0.02	0.05	0.22	0.07
	10	0.02	0.05	0.09	0.21	0.03		10	0.02	0.04	0.06	0.22	0.07
	20	0.03	0.07	0.12	0.20	0.03		20	0.02	0.05	0.07	0.20	0.07
	30	0.04	0.08	0.12	0.17	0.03		30	0.02	0.04	0.07	0.18	0.07
	40	0.04	0.08	0.10	0.13	0.03		40	0.02	0.05	0.08	0.16	0.06
	50	0.04	0.06	0.08	0.09	0.03		50	0.03	0.06	0.11	0.14	0.06
	60	0.03	0.05	0.06	0.06	0.02		60	0.04	0.09	0.11	0.13	0.06
	70	0.03	0.04	-	0.04	0.02		70	0.05	0.08	-	0.10	0.06
80	0.02	-	-	0.02	0.01	80	0.04	-	-	0.06	0.04		

Devcan 6.7.4, August 2016, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: Incidence data are from the SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG). Mortality data are from the NCHS public use data file for the total US.

^a Underlying incidence and mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

- Statistic could not be calculated.

A percent of 0.00 represents a value that is below 0.005.

Table 9.14
Hodgkin Lymphoma

Risk of Being Diagnosed With Cancer in 10, 20 and 30 Years,
Lifetime Risk of Being Diagnosed with Cancer Given Alive and Cancer-Free at Current Age, and
Lifetime Risk of Dying from Cancer Given Alive at Current Age
Females, 2011-2013 By Race/Ethnicity

Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer					Risk of Dying from Cancer	Race/ Ethnicity	Current Age	Risk of Being Diagnosed with Cancer					Risk of Dying from Cancer
		+10 yrs	+20 yrs	+30 yrs	Ever	+10 yrs				+20 yrs	+30 yrs	Ever			
All Races	0	0.00	0.02	0.06	0.19	0.03	Asian/ Pacific Islander	0	0.00	0.01	0.04	0.10	0.02		
	10	0.02	0.06	0.09	0.19	0.03		10	0.01	0.04	0.05	0.10	0.02		
	20	0.04	0.07	0.09	0.17	0.03		20	0.02	0.04	0.05	0.09	0.02		
	30	0.03	0.05	0.07	0.13	0.03		30	0.02	0.02	0.03	0.06	0.02		
	40	0.02	0.04	0.06	0.10	0.03		40	0.01	0.01	0.02	0.05	0.02		
	50	0.02	0.04	0.06	0.09	0.03		50	0.01	0.01	0.03	0.04	0.02		
	60	0.02	0.05	0.07	0.07	0.03		60	0.01	0.02	0.04	0.04	0.02		
	70	0.03	0.05	-	0.05	0.02		70	0.01	0.03	-	0.03	0.02		
80	0.03	-	-	0.03	0.02	80	0.02	-	-	0.02	0.02				
White	0	0.00	0.02	0.07	0.20	0.03	American Indian/ Alaska Native ^a	0	0.00	0.01	0.01	0.09	0.01		
	10	0.02	0.07	0.10	0.21	0.03		10	0.01	0.01	0.01	0.09	0.01		
	20	0.04	0.08	0.10	0.18	0.03		20	0.01	0.01	0.01	0.08	0.01		
	30	0.03	0.05	0.07	0.14	0.03		30	0.00	0.00	0.03	0.08	0.01		
	40	0.02	0.04	0.06	0.11	0.03		40	0.00	0.03	0.03	0.08	0.01		
	50	0.02	0.04	0.07	0.09	0.03		50	0.03	0.03	0.05	0.08	0.01		
	60	0.02	0.05	0.07	0.07	0.03		60	0.01	0.02	0.06	0.06	0.01		
	70	0.03	0.05	-	0.06	0.02		70	0.02	0.06	-	0.06	0.01		
80	0.03	-	-	0.03	0.02	80	0.05	-	-	0.05	0.00				
Black	0	0.00	0.02	0.05	0.17	0.02	Hispanic ^b	0	0.00	0.02	0.04	0.18	0.04		
	10	0.02	0.05	0.08	0.17	0.02		10	0.02	0.04	0.06	0.18	0.04		
	20	0.03	0.06	0.09	0.16	0.02		20	0.03	0.04	0.06	0.16	0.04		
	30	0.03	0.05	0.07	0.13	0.02		30	0.02	0.03	0.05	0.14	0.04		
	40	0.02	0.04	0.07	0.10	0.02		40	0.02	0.03	0.05	0.12	0.04		
	50	0.02	0.05	0.06	0.08	0.02		50	0.02	0.04	0.08	0.11	0.04		
	60	0.03	0.05	0.06	0.06	0.01		60	0.02	0.06	0.09	0.09	0.04		
	70	0.02	0.03	-	0.03	0.01		70	0.04	0.07	-	0.08	0.04		
80	0.02	-	-	0.02	0.01	80	0.03	-	-	0.04	0.03				

Devcan 6.7.4, August 2016, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: Incidence data are from the SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG). Mortality data are from the NCHS public use data file for the total US.

^a Underlying incidence and mortality data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

- Statistic could not be calculated.

A percent of 0.00 represents a value that is below 0.005.

Table 9.15
Hodgkin Lymphoma

SEER Incidence and U.S. Mortality
Age-Adjusted Rates and Trends^a
By Race/Ethnicity and Sex

SEER Incidence	SEER 18 Areas ^b			SEER 13 Areas ^b			SEER 9 Areas ^b		
	Rate 2009-2013			Trend 2004-2013 ^c			Trend 2004-2013 ^d		
	Rate per 100,000 persons			AAPC (%)			AAPC (%)		
RACE/ETHNICITY	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Races	2.6	3.0	2.3	-1.3*	-1.0*	-0.2	-1.2*	-0.8	-1.5
White	2.8	3.1	2.5	-1.5*	-0.1	-1.9	-1.4*	-0.7	-1.8
White Hispanic ^e	2.3	2.6	2.0	0.0	-0.5	0.5	-	-	-
White Non-Hispanic ^e	3.0	3.4	2.7	-1.7*	0.1	-2.1*	-	-	-
Black	2.6	3.0	2.2	0.8*	1.0*	0.4	1.1*	0.5	1.8*
Asian/Pacific Islander	1.3	1.5	1.2	-0.2	1.3	2.3*	-	-	-
Amer Ind/Alaska Nat ^f	1.2	1.5	1.0	-	-	-	-	-	-
Hispanic ^e	2.2	2.5	1.9	0.0	-0.5	0.5	-	-	-
<u>U.S. Mortality^g</u>									
RACE/ETHNICITY	Rate 2009-2013			Trend 2004-2013 ^h					
	Rate per 100,000 persons			AAPC (%)					
	Total	Males	Females	Total	Males	Females			
All Races	0.4	0.5	0.3	-2.8*	-2.4*	-2.9*			
White	0.4	0.5	0.3	-2.7*	-2.3*	-2.8*			
White Hispanic ^e	0.4	0.6	0.3	-2.2*	-2.3*	-2.2*			
White Non-Hispanic ^e	0.4	0.5	0.3	-2.7*	-2.6*	-2.8*			
Black	0.3	0.4	0.3	-2.9*	-3.3*	-2.5*			
Asian/Pacific Islander	0.1	0.2	0.1	-2.1*	-2.7*	-			
Amer Ind/Alaska Nat									
Total U.S.	0.1	-	-	-3.0	-	-			
CHSDA Counties	-	-	-	-1.0	-	-			
Non-CHSDA Counties	-	-	-	-	-	-			
Hispanic ^e	0.4	0.6	0.3	-2.4*	-2.4*	-2.4*			

The AAPC is the Average Annual Percent Change over the time interval. The AAPCs are calculated by the Joinpoint Regression Program Version 4.3.0.0, April 2016, National Cancer Institute.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130). Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

b The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta.

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry, and Rural Georgia.

The SEER 18 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG.

c The 2004-2013 AAPC estimates are based on a Joinpoint analysis with up to 4 Joinpoints over diagnosis years 1992-2013.

d The 2004-2013 AAPC estimates are based on a Joinpoint analysis with up to 5 Joinpoints over diagnosis years 1975-2013.

e Hispanic and Non-Hispanic are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. The 2004-2013 Hispanic and Non-Hispanic mortality trends exclude deaths from New Hampshire and Oklahoma.

f Incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

g US Mortality Files, National Center for Health Statistics, CDC.

h The 2004-2013 mortality AAPCs are based on a Joinpoint analysis using years of death 1992-2013.

* The APC is significantly different from zero (p<.05).

Table 9.16
Hodgkin Lymphoma

Age-Adjusted SEER Incidence Rates^a
By Registry, Race and Sex

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>SEER Incidence Rates^a, 2009-2013</u>									
California	2.34	2.69	2.03	2.54	2.89	2.23	2.61	3.17	2.09
Greater Bay Area	2.39	2.72	2.12	2.75	3.13	2.42	3.29	3.90	2.71
San Francisco-Oakland	2.47	2.82	2.17	2.84	3.30	2.45	3.51	3.94	3.12
San Jose-Monterey	2.24	2.53	2.01	2.59	2.84	2.39	-	-	-
Los Angeles	2.33	2.71	1.99	2.55	2.97	2.18	2.56	2.91	2.26
Greater California	2.34	2.68	2.02	2.49	2.81	2.20	2.42	3.06	1.73
Connecticut	3.44	3.82	3.12	3.54	3.89	3.22	3.07	3.78	2.49
Detroit	3.04	3.56	2.57	3.41	3.96	2.91	2.26	2.67	1.85
Georgia	2.43	2.67	2.23	2.44	2.59	2.33	2.55	3.03	2.18
Atlanta	2.51	2.86	2.21	2.54	2.85	2.26	2.65	3.13	2.28
Rural Georgia	2.69	-	-	-	-	-	-	-	-
Greater Georgia	2.37	2.55	2.23	2.41	2.49	2.36	2.41	2.86	2.05
Hawaii	1.83	2.00	1.69	2.78	3.00	2.55	-	-	-
Iowa	3.07	3.48	2.67	3.10	3.51	2.71	-	-	-
Kentucky	2.74	3.05	2.43	2.76	3.09	2.43	2.58	2.21	2.92
Louisiana	2.76	3.01	2.53	2.85	3.06	2.67	2.52	2.78	2.25
New Jersey	3.27	3.66	2.94	3.47	3.87	3.13	2.89	3.23	2.63
New Mexico	2.26	2.65	1.93	2.39	2.70	2.13	-	-	-
Seattle-Puget Sound	2.81	3.32	2.32	2.89	3.39	2.40	3.82	4.52	3.01
Utah	2.55	2.66	2.45	2.59	2.67	2.53	-	-	-
SEER 9 Areas ^b	2.76	3.14	2.42	2.96	3.34	2.62	2.73	3.21	2.30
SEER 13 Areas ^b	2.62	2.98	2.29	2.83	3.21	2.49	2.70	3.19	2.27
SEER 18 Areas ^b	2.61	2.95	2.30	2.78	3.11	2.48	2.62	3.04	2.24

^a Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130)

^b The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta.

The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia.

The SEER 18 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 9.17
Hodgkin Lymphoma

Age-Adjusted SEER Death Rates^a
By Registry, Race and Sex

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>SEER Death Rates^a, 2009-2013</u>									
California	0.38	0.50	0.28	0.42	0.55	0.32	0.33	0.51	-
Greater Bay Area	0.33	0.45	0.23	0.39	0.49	0.32	-	-	-
San Francisco-Oakland	0.33	0.49	0.19	0.39	0.54	0.26	-	-	-
San Jose-Monterey	0.33	0.37	0.31	0.39	0.40	0.41	-	-	-
Los Angeles	0.40	0.54	0.31	0.46	0.59	0.36	-	-	-
Greater California	0.38	0.50	0.28	0.42	0.55	0.31	0.40	-	-
Connecticut	0.32	0.35	0.28	0.32	0.35	0.28	-	-	-
Detroit	0.38	0.44	0.32	0.41	0.45	0.38	-	-	-
Georgia	0.36	0.51	0.26	0.36	0.50	0.28	0.37	0.49	0.26
Atlanta	0.29	0.49	-	0.31	0.53	-	0.27	-	-
Rural Georgia	-	-	-	-	-	-	-	-	-
Greater Georgia	0.38	0.51	0.31	0.38	0.49	0.33	0.38	0.50	-
Hawaii	0.21	-	-	-	-	-	-	-	-
Iowa	0.36	0.47	0.28	0.36	0.47	0.27	-	-	-
Kentucky	0.27	0.32	0.23	0.28	0.32	0.22	-	-	-
Louisiana	0.47	0.55	0.42	0.51	0.58	0.46	0.35	-	-
New Jersey	0.32	0.38	0.27	0.35	0.42	0.30	0.30	-	-
New Mexico	0.37	0.54	-	0.39	0.55	-	-	-	-
Seattle-Puget Sound	0.26	0.30	0.22	0.28	0.34	0.23	-	-	-
Utah	0.26	0.33	-	0.27	0.35	-	-	-	-
SEER 9 Areas ^b	0.32	0.41	0.23	0.34	0.43	0.25	0.31	0.44	0.20
SEER 13 Areas ^b	0.34	0.43	0.26	0.36	0.46	0.29	0.31	0.44	0.20
SEER 18 Areas ^b	0.35	0.45	0.27	0.38	0.47	0.30	0.33	0.44	0.24
Total U.S.	0.36	0.45	0.28	0.37	0.47	0.30	0.33	0.42	0.26

^a US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b The SEER 9 areas are San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta. The SEER 13 areas comprise the SEER 9 areas plus San Jose-Monterey, Los Angeles, the Alaska Native Registry and Rural Georgia. The SEER 18 areas comprise the SEER 13 areas plus California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG.

- Statistic not shown. Rate based on less than 16 cases for the time interval.



Table 9.18
Hodgkin Lymphoma

Age-Adjusted Cancer Death^a Rates By State, All Races, 2009-2013

Males and Females

State	Rate	SE	Rank(CI) ^d	PD
TOTAL U.S.	0.36	0.00		
High Five States				
Vermont	0.64	0.14	01(01,43)	77.81 ^c
Louisiana	0.47	0.05	02(01,28)	32.63 ^c
West Virginia	0.44	0.07	03(01,43)	23.49 ^c
Mississippi	0.44	0.05	04(01,42)	23.42 ^c
New Hampshire	0.43	0.08	05(01,46)	19.17 ^c
Low Five States				
Arizona	0.29	0.03	42(15,46)	-18.22 ^c
Colorado	0.28	0.03	43(14,46)	-22.76 ^c
Kentucky	0.27	0.04	44(15,46)	-23.40 ^c
Utah	0.26	0.05	45(07,46)	-26.38 ^c
Hawaii	0.21	0.05	46(13,46)	-41.54 ^c

State	Rate	SE	Rank(CI) ^d	PD	State	Rate	SE	Rank(CI) ^d	PD
Alabama	0.38	0.04	13(02,43)	6.99	Montana	0.34	0.08	35(01,46)	-5.86
Alaska	-	-	-(-,-)	-	Nebraska	0.36	0.06	26(01,46)	0.93
Arizona	0.29	0.03	42(15,46)	-18.22 ^c	Nevada	0.32	0.05	38(03,46)	-9.47
Arkansas	0.40	0.05	10(01,44)	12.08	New Hampshire	0.43	0.08	05(01,46)	19.17 ^c
California	0.38	0.01	15(06,32)	5.98	New Jersey	0.32	0.03	37(10,45)	-9.44
Colorado	0.28	0.03	43(14,46)	-22.76 ^c	New Mexico	0.37	0.06	18(01,46)	4.63
Connecticut	0.32	0.04	39(05,46)	-11.30	New York	0.36	0.02	27(08,39)	0.91
Delaware	0.37	0.09	17(01,46)	4.78	North Carolina	0.34	0.03	34(08,44)	-5.01
D.C.	-	-	-(-,-)	-	North Dakota	-	-	-(-,-)	-
Florida	0.35	0.02	28(09,40)	-0.95	Ohio	0.36	0.02	25(05,41)	1.07
Georgia	0.36	0.03	24(04,42)	1.10	Oklahoma	0.40	0.05	09(01,43)	13.18
Hawaii	0.21	0.05	46(13,46)	-41.54 ^c	Oregon	0.36	0.04	23(02,45)	1.69
Idaho	0.41	0.07	08(01,46)	13.80	Pennsylvania	0.37	0.02	19(05,38)	3.50
Illinois	0.31	0.02	41(18,45)	-13.81	Rhode Island	0.41	0.08	07(01,46)	14.99
Indiana	0.35	0.03	31(04,44)	-1.50	South Carolina	0.33	0.04	36(05,46)	-6.73
Iowa	0.36	0.05	22(02,45)	1.92	South Dakota	-	-	-(-,-)	-
Kansas	0.37	0.05	20(02,45)	2.66	Tennessee	0.42	0.04	06(01,35)	18.15 ^c
Kentucky	0.27	0.04	44(15,46)	-23.40 ^c	Texas	0.39	0.02	11(05,34)	8.17
Louisiana	0.47	0.05	02(01,28)	32.63 ^c	Utah	0.26	0.05	45(07,46)	-26.38 ^c
Maine	0.38	0.07	16(01,46)	5.22	Vermont	0.64	0.14	01(01,43)	77.81 ^c
Maryland	0.35	0.03	32(04,44)	-1.63	Virginia	0.35	0.03	29(05,43)	-0.95
Massachusetts	0.34	0.03	33(05,45)	-3.94	Washington	0.31	0.03	40(10,46)	-12.56
Michigan	0.38	0.03	12(03,39)	7.58	West Virginia	0.44	0.07	03(01,43)	23.49 ^c
Minnesota	0.35	0.04	30(04,45)	-1.44	Wisconsin	0.38	0.04	14(02,42)	6.93
Mississippi	0.44	0.05	04(01,42)	23.42 ^c	Wyoming	-	-	-(-,-)	-
Missouri	0.37	0.03	21(03,43)	2.42					



^a US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b Difference between state rate and total U.S. rate is statistically significant ($p < .0002$).

^c Absolute percent difference between state rate and total U.S. rate is 15% or more.

^d Rank of state level death rate and the 95% confidence intervals (low, high) for the rank.

SE Standard error of the rate.

PD Percent difference between state rate and total U.S. rate.

- Statistic not shown. Rate based on less than 16 cases for the time interval.


Table 9.19
Hodgkin Lymphoma

Age-Adjusted Cancer Death^a Rates By State, All Races, 2009-2013

Males

State	Rate	SE	Rank(CI) ^d	PD
TOTAL U.S.	0.45	0.01		
High Five States				
New Hampshire	0.62	0.15	01(01,42)	37.91 ^c
Rhode Island	0.59	0.15	02(01,42)	30.82 ^c
Tennessee	0.58	0.06	03(01,30)	29.31 ^c
Nebraska	0.56	0.11	04(01,41)	23.99 ^c
Mississippi	0.56	0.09	05(01,40)	23.29 ^c
Low Five States				
Connecticut	0.35	0.06	38(06,42)	-21.67 ^c
Arizona	0.34	0.05	39(15,42)	-23.56 ^c
Utah	0.33	0.08	40(04,42)	-26.57 ^c
Kentucky	0.32	0.06	41(14,42)	-29.85 ^c
Colorado	0.28	0.05	42(24,42)	-38.91 ^c

State	Rate	SE	Rank(CI) ^d	PD	State	Rate	SE	Rank(CI) ^d	PD
Alabama	0.44	0.06	28(02,41)	-1.84	Montana	-	-	-(-,-)	-
Alaska	-	-	-(-,-)	-	Nebraska	0.56	0.11	04(01,41)	23.99 ^c
Arizona	0.34	0.05	39(15,42)	-23.56 ^c	Nevada	0.41	0.08	34(02,42)	-8.58
Arkansas	0.46	0.08	19(01,42)	1.88	New Hampshire	0.62	0.15	01(01,42)	37.91 ^c
California	0.50	0.02	11(04,28)	11.29	New Jersey	0.38	0.04	36(10,42)	-14.69
Colorado	0.28	0.05	42(24,42)	-38.91 ^c	New Mexico	0.54	0.11	07(01,42)	19.06 ^c
Connecticut	0.35	0.06	38(06,42)	-21.67 ^c	New York	0.45	0.03	26(07,38)	-1.28
Delaware	-	-	-(-,-)	-	North Carolina	0.45	0.05	23(04,40)	-0.70
D.C.	-	-	-(-,-)	-	North Dakota	-	-	-(-,-)	-
Florida	0.44	0.03	30(09,38)	-2.62	Ohio	0.45	0.04	22(04,38)	0.16
Georgia	0.51	0.05	09(01,36)	13.32	Oklahoma	0.47	0.07	15(01,41)	5.24
Hawaii	-	-	-(-,-)	-	Oregon	0.50	0.07	13(01,40)	10.14
Idaho	0.45	0.11	24(01,42)	-1.03	Pennsylvania	0.42	0.04	32(08,40)	-6.79
Illinois	0.39	0.04	35(12,41)	-14.56	Rhode Island	0.59	0.15	02(01,42)	30.82 ^c
Indiana	0.46	0.06	21(02,40)	1.74	South Carolina	0.46	0.06	20(02,41)	1.83
Iowa	0.47	0.08	17(01,42)	4.93	South Dakota	-	-	-(-,-)	-
Kansas	0.44	0.08	31(01,42)	-3.36	Tennessee	0.58	0.06	03(01,30)	29.31 ^c
Kentucky	0.32	0.06	41(14,42)	-29.85 ^c	Texas	0.52	0.03	08(02,26)	16.36 ^c
Louisiana	0.55	0.07	06(01,38)	20.94 ^c	Utah	0.33	0.08	40(04,42)	-26.57 ^c
Maine	0.50	0.12	10(01,42)	11.45	Vermont	-	-	-(-,-)	-
Maryland	0.42	0.06	33(04,42)	-7.62	Virginia	0.50	0.05	12(01,38)	10.72
Massachusetts	0.45	0.05	25(03,40)	-1.05	Washington	0.36	0.05	37(11,42)	-20.49 ^c
Michigan	0.48	0.05	14(02,37)	7.30	West Virginia	0.47	0.10	16(01,42)	4.96
Minnesota	0.44	0.06	27(02,41)	-1.65	Wisconsin	0.47	0.06	18(02,40)	3.59
Mississippi	0.56	0.09	05(01,40)	23.29 ^c	Wyoming	-	-	-(-,-)	-
Missouri	0.44	0.06	29(03,41)	-2.10					



^a US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b Difference between state rate and total U.S. rate is statistically significant ($p < .0002$).

^c Absolute percent difference between state rate and total U.S. rate is 15% or more.

^d Rank of state level death rate and the 95% confidence intervals (low, high) for the rank.

SE Standard error of the rate.

PD Percent difference between state rate and total U.S. rate.

- Statistic not shown. Rate based on less than 16 cases for the time interval.


Table 9.20
Hodgkin Lymphoma

Age-Adjusted Cancer Death^a Rates By State, All Races, 2009-2013

Females

State	Rate	SE	Rank(CI) ^d	PD
TOTAL U.S.	0.28	0.01		
High Five States				
Louisiana	0.42	0.06	01(01,24)	51.42 ^c
West Virginia	0.41	0.09	02(01,34)	47.88 ^c
Mississippi	0.36	0.07	03(01,34)	30.09 ^c
Oklahoma	0.36	0.06	04(01,34)	29.74 ^c
Arkansas	0.36	0.07	05(01,34)	29.00 ^c
Low Five States				
Arizona	0.25	0.04	31(05,35)	-12.02
Nevada	0.25	0.06	32(02,35)	-12.18
Illinois	0.25	0.03	33(08,35)	-12.44
Kentucky	0.23	0.04	34(04,35)	-18.98 ^c
South Carolina	0.22	0.04	35(06,35)	-23.08 ^c

State	Rate	SE	Rank(CI) ^d	PD	State	Rate	SE	Rank(CI) ^d	PD
Alabama	0.33	0.05	07(01,34)	16.66 ^c	Montana	-	-	-(-,-)	-
Alaska	-	-	-(-,-)	-	Nebraska	-	-	-(-,-)	-
Arizona	0.25	0.04	31(05,35)	-12.02	Nevada	0.25	0.06	32(02,35)	-12.18
Arkansas	0.36	0.07	05(01,34)	29.00 ^c	New Hampshire	-	-	-(-,-)	-
California	0.28	0.02	16(07,31)	-0.24	New Jersey	0.27	0.03	24(04,35)	-2.83
Colorado	0.27	0.05	25(02,35)	-2.92	New Mexico	-	-	-(-,-)	-
Connecticut	0.28	0.05	19(02,35)	-0.61	New York	0.29	0.02	12(04,31)	4.94
Delaware	-	-	-(-,-)	-	North Carolina	0.25	0.03	29(06,35)	-10.93
D.C.	-	-	-(-,-)	-	North Dakota	-	-	-(-,-)	-
Florida	0.28	0.02	17(05,33)	-0.26	Ohio	0.29	0.03	14(03,34)	1.88
Georgia	0.26	0.03	26(04,35)	-6.28	Oklahoma	0.36	0.06	04(01,34)	29.74 ^c
Hawaii	-	-	-(-,-)	-	Oregon	0.25	0.05	28(03,35)	-9.93
Idaho	-	-	-(-,-)	-	Pennsylvania	0.33	0.03	06(01,27)	17.62 ^c
Illinois	0.25	0.03	33(08,35)	-12.44	Rhode Island	-	-	-(-,-)	-
Indiana	0.28	0.04	20(03,35)	-1.28	South Carolina	0.22	0.04	35(06,35)	-23.08 ^c
Iowa	0.28	0.06	18(01,35)	-0.50	South Dakota	-	-	-(-,-)	-
Kansas	0.31	0.07	08(01,35)	11.97	Tennessee	0.28	0.04	15(02,35)	1.63
Kentucky	0.23	0.04	34(04,35)	-18.98 ^c	Texas	0.27	0.02	22(07,33)	-1.93
Louisiana	0.42	0.06	01(01,24)	51.42 ^c	Utah	-	-	-(-,-)	-
Maine	-	-	-(-,-)	-	Vermont	-	-	-(-,-)	-
Maryland	0.29	0.04	13(02,35)	2.72	Virginia	0.25	0.03	30(06,35)	-11.66
Massachusetts	0.26	0.04	27(04,35)	-7.98	Washington	0.28	0.04	21(03,35)	-1.36
Michigan	0.30	0.03	11(02,33)	5.80	West Virginia	0.41	0.09	02(01,34)	47.88 ^c
Minnesota	0.27	0.04	23(02,35)	-1.96	Wisconsin	0.31	0.04	09(01,34)	10.14
Mississippi	0.36	0.07	03(01,34)	30.09 ^c	Wyoming	-	-	-(-,-)	-
Missouri	0.31	0.04	10(01,35)	9.59					



^a US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention. Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^b Difference between state rate and total U.S. rate is statistically significant ($p < .0002$).

^c Absolute percent difference between state rate and total U.S. rate is 15% or more.

^d Rank of state level death rate and the 95% confidence intervals (low, high) for the rank.

SE Standard error of the rate.

PD Percent difference between state rate and total U.S. rate.

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Table 9.21
Hodgkin LymphomaEstimated United States Cancer Prevalence Counts^a on January 1, 2013
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <21 ^e	0 to <38 ^e	>=38 ^g	Complete ^h
<u>Race</u>	<u>Sex</u>										
All Races ^b	Both Sexes	37,358	34,292	28,727	25,325	22,323	17,430	139,536	181,370	12,175	193,545
	Males	20,235	18,129	14,510	12,916	11,125	8,871	72,770	94,047	6,049	100,096
	Females	17,123	16,163	14,217	12,409	11,198	8,559	66,766	87,323	6,126	93,449
White ^b	Both Sexes	30,903	28,953	24,933	22,403	20,422	16,164	119,721	158,840	13,473	172,313
	Males	16,904	15,439	12,599	11,460	10,227	8,058	62,752	82,343	6,989	89,332
	Females	13,999	13,514	12,334	10,943	10,195	8,106	56,969	76,497	6,484	82,981
Black ^b	Both Sexes	4,743	4,127	2,817	2,469	1,501	1,031	15,221	17,329	957	18,286
	Males	2,438	2,028	1,369	1,240	698	695	7,586	8,960	667	9,627
	Females	2,305	2,099	1,448	1,229	803	336	7,635	8,369	290	8,659
Asian/ Pacific Islander ^c	Both Sexes	999	838	567	+	+	+	2,742	+	+	+
	Males	503	434	304	+	+	+	1,382	+	+	+
	Females	496	404	263	+	+	+	1,360	+	+	+
Hispanic ^d	Both Sexes	4,295	3,436	2,580	+	+	+	12,418	+	+	+
	Males	2,290	1,890	1,438	+	+	+	6,757	+	+	+
	Females	2,005	1,546	1,142	+	+	+	5,661	+	+	+

Estimated prevalence percent^a on January 1, 2013, of the SEER^c population diagnosed in the previous 21 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)									Age-Adjusted ^f	
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races ^c	Both Sexes	0.0377%	0.0006%	0.0104%	0.0393%	0.0655%	0.0655%	0.0469%	0.0369%	0.0338%	0.0251%	0.0376%
	Males	0.0400%	0.0009%	0.0115%	0.0392%	0.0634%	0.0694%	0.0534%	0.0449%	0.0404%	0.0273%	0.0398%
	Females	0.0354%	0.0003%	0.0092%	0.0393%	0.0676%	0.0616%	0.0407%	0.0295%	0.0284%	0.0237%	0.0356%
White ^c	Both Sexes	0.0429%	0.0006%	0.0115%	0.0444%	0.0754%	0.0753%	0.0529%	0.0415%	0.0383%	0.0285%	0.0429%
	Males	0.0454%	0.0008%	0.0127%	0.0440%	0.0721%	0.0791%	0.0594%	0.0508%	0.0451%	0.0310%	0.0450%
	Females	0.0404%	0.0005%	0.0102%	0.0449%	0.0789%	0.0714%	0.0464%	0.0329%	0.0326%	0.0270%	0.0410%
Black ^c	Both Sexes	0.0340%	0.0007%	0.0095%	0.0314%	0.0613%	0.0650%	0.0467%	0.0348%	0.0296%	0.0179%	0.0351%
	Males	0.0352%	0.0013%	0.0099%	0.0294%	0.0606%	0.0681%	0.0571%	0.0365%	0.0383%	0.0218%	0.0371%
	Females	0.0329%	-	0.0092%	0.0333%	0.0620%	0.0623%	0.0376%	0.0336%	0.0236%	0.0160%	0.0335%
Asian/ Pacific Islander ^c	Both Sexes	0.0146%	-	0.0054%	0.0220%	0.0263%	0.0194%	0.0148%	0.0100%	0.0116%	0.0066%	0.0139%
	Males	0.0154%	-	0.0067%	0.0256%	0.0246%	0.0196%	0.0147%	0.0115%	0.0159%	0.0076%	0.0148%
	Females	0.0139%	-	0.0040%	0.0184%	0.0279%	0.0192%	0.0148%	0.0088%	0.0083%	0.0060%	0.0131%
Hispanic ^d	Both Sexes	0.0235%	0.0009%	0.0097%	0.0275%	0.0378%	0.0366%	0.0322%	0.0363%	0.0368%	0.0241%	0.0257%
	Males	0.0253%	0.0010%	0.0125%	0.0288%	0.0355%	0.0395%	0.0399%	0.0408%	0.0411%	0.0350%	0.0282%
	Females	0.0217%	0.0008%	0.0068%	0.0261%	0.0402%	0.0335%	0.0248%	0.0324%	0.0336%	0.0176%	0.0235%

^a US 2013 cancer prevalence counts are based on 2013 cancer prevalence proportions from the SEER registries and 1/1/2013 US population estimates based on the average of 2012 and 2013 population estimates from the US Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

^{b c d} Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry

(d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.

^e Maximum limited-duration prevalence: 38 years for 1975-2013 SEER 9 data; 21 years for 1992-2013 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.

^f Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^{g h i} (g) Cases diagnosed more than 38 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <38 and >=38. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 9.22
All Lymphoid Neoplasms With Detailed Hodgkin Lymphoma Subtypes^a

SEER^b Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Both Sexes, 2004-2013

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
Lymphoid Neoplasm	35.9	305,874	-0.4*	5.9	14,053	0.3	23.6	129,762	-0.6*	161.2	162,059	-0.3
1 Hodgkin Lymphoma	2.7	23,173	-1.5*	1.2	2,903	-0.5	3.2	16,148	-1.3*	4.1	4,122	-2.9*
1(a) Classical Hodgkin lymphoma	2.6	21,895	-1.8*	1.1	2,713	-1.1	3.0	15,266	-1.5*	3.9	3,916	-3.3*
1(a)1. Lymphocyte-rich/mixed cellularity/ lymphocyte-depleted	0.4	3,690	-3.2*	0.1	319	0.9	0.5	2,355	-2.3*	1.0	1,016	-6.2*
1(a)1.1 Lymphocyte-rich	0.1	744	-3.0	0.0	67	-	0.1	500	-2.6	0.2	177	-4.4
1(a)1.2 Mixed cellularity	0.3	2,665	-2.9*	0.1	234	1.6	0.3	1,704	-2.0*	0.7	727	-6.4*
1(a)1.3 Lymphocyte-depleted	0.0	281	-5.8	0.0	18	-	0.0	151	-	0.1	112	-
1(a)2. Nodular sclerosis	1.5	12,685	-3.4*	0.8	1,997	-2.9*	1.8	9,335	-3.2*	1.3	1,353	-5.1*
1(a)3. Classical Hodgkin lymphoma, NOS ^c	0.6	5,520	2.9*	0.2	397	7.2*	0.7	3,576	3.6*	1.5	1,547	0.5
1(b) Nodular lymphocyte predominant Hodgkin Lymphoma	0.1	1,278	4.9*	0.1	190	9.1*	0.2	882	4.2*	0.2	206	4.3*
2 Non-Hodgkin lymphoma	32.2	274,206	-0.2	4.7	11,024	0.3	19.9	110,735	-0.4*	151.7	152,447	-0.1
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	0.0	249	22.7*	-	-	-	0.0	132	-	0.1	111	-
4 Lymphoid neoplasm, NOS ^c	1.0	8,246	-5.0*	0.1	120	-	0.5	2,747	-4.8*	5.3	5,379	-5.4*

^a The APC is the Annual Percent Change over the time interval.

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified.

* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 9.23
All Lymphoid Neoplasms With Detailed Hodgkin Lymphoma Subtypes^a

SEER^b Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Males, 2004-2013

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
Lymphoid Neoplasm	44.4	170,501	-0.3	6.8	8,174	0.1	28.1	75,839	-0.7*	205.8	86,488	-0.1
1 Hodgkin Lymphoma	3.1	12,673	-1.3*	1.3	1,566	0.3	3.5	8,934	-1.2*	5.1	2,173	-2.5*
1(a) Classical Hodgkin lymphoma	2.9	11,796	-1.7*	1.2	1,413	-0.7	3.3	8,329	-1.5*	4.8	2,054	-2.6*
1(a)1. Lymphocyte-rich/mixed cellularity/ lymphocyte-depleted	0.6	2,302	-2.5*	0.2	228	2.1	0.6	1,565	-2.2*	1.2	509	-4.8*
1(a)1.1 Lymphocyte-rich	0.1	440	-3.8*	0.0	54	-	0.1	307	-3.8	0.2	79	-
1(a)1.2 Mixed cellularity	0.4	1,697	-1.7	0.1	164	2.9	0.5	1,158	-1.6	0.9	375	-3.4
1(a)1.3 Lymphocyte-depleted	0.0	165	-	-	-	-	0.0	100	-	0.1	55	-
1(a)2. Nodular sclerosis	1.5	6,334	-3.4*	0.8	968	-2.7	1.8	4,653	-3.4*	1.7	713	-4.2
1(a)3. Classical Hodgkin lymphoma, NOS ^c	0.8	3,160	2.5*	0.2	217	5.4*	0.8	2,111	3.5*	2.0	832	0.0
1(b) Nodular lymphocyte predominant Hodgkin Lymphoma	0.2	877	4.6*	0.1	153	10.0*	0.2	605	4.4*	0.3	119	-
2 Non-Hodgkin lymphoma	40.2	153,352	-0.1	5.4	6,527	-0.2	24.0	65,193	-0.5*	194.1	81,632	0.2
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	0.0	138	-	-	-	-	0.0	79	-	0.1	54	-
4 Lymphoid neoplasm, NOS ^c	1.2	4,338	-4.7*	0.1	76	-	0.6	1,633	-5.8*	6.4	2,629	-4.7*

^a The APC is the Annual Percent Change over the time interval.

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified.

* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 9.24
 All Lymphoid Neoplasms With Detailed Hodgkin Lymphoma Subtypes^a
 SEER^b Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Females, 2004-2013

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
Lymphoid Neoplasm	29.1	135,373	-0.6*	5.1	5,879	0.5	19.3	53,923	-0.4	129.5	75,571	-0.8*
1 Hodgkin Lymphoma	2.4	10,500	-1.8*	1.1	1,337	-1.4	2.8	7,214	-1.4*	3.4	1,949	-3.6*
1(a) Classical Hodgkin lymphoma	2.3	10,099	-2.1*	1.1	1,300	-1.6	2.7	6,937	-1.6*	3.2	1,862	-4.2*
1(a)1. Lymphocyte-rich/mixed cellularity/ lymphocyte-depleted	0.3	1,388	-4.3*	0.1	91	-	0.3	790	-2.5	0.9	507	-7.6*
1(a)1.1 Lymphocyte-rich	0.1	304	-1.7	-	-	-	0.1	193	-0.4	0.2	98	-
1(a)1.2 Mixed cellularity	0.2	968	-5.0*	0.1	70	-	0.2	546	-2.7	0.6	352	-9.6*
1(a)1.3 Lymphocyte-depleted	0.0	116	-	-	-	-	0.0	51	-	0.1	57	-
1(a)2. Nodular sclerosis	1.5	6,351	-3.4*	0.9	1,029	-3.2	1.9	4,682	-3.0*	1.1	640	-6.2*
1(a)3. Classical Hodgkin lymphoma, NOS ^c	0.5	2,360	3.3*	0.2	180	-	0.6	1,465	3.8*	1.2	715	0.4
1(b) Nodular lymphocyte predominant Hodgkin Lymphoma	0.1	401	5.3*	0.0	37	-	0.1	277	3.8	0.2	87	-
2 Non-Hodgkin lymphoma	25.9	120,854	-0.3	3.9	4,497	1.0	16.0	45,542	-0.1	121.5	70,815	-0.5*
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	0.0	111	-	-	-	-	0.0	53	-	0.1	57	-
4 Lymphoid neoplasm, NOS ^c	0.8	3,908	-5.1*	0.0	44	-	0.4	1,114	-3.3*	4.5	2,750	-6.2*

The APC is the Annual Percent Change over the time interval.

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified.

* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 9.25
All Lymphoid Neoplasms With Detailed Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Both Sexes, 2006-2012

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	
Lymphoid Neoplasm	175,423	69.9 (69.6 , 70.1)	90.1 (89.4 , 90.7)	77.3 (77.0 , 77.7)	59.4 (58.9 , 59.9)			
1 Hodgkin Lymphoma	14,954	86.2 (85.6 , 86.9)	96.9 (95.8 , 97.6)	90.2 (89.5 , 90.9)	54.3 (51.3 , 57.3)			
1(a) Classical Hodgkin lymphoma	14,149	85.7 (85.0 , 86.4)	96.7 (95.6 , 97.5)	89.9 (89.2 , 90.6)	52.4 (49.3 , 55.4)			
1(a)1. Lymphocyte-rich/mixed cellularity/ lymphocyte-depleted	2,333	81.6 (79.5 , 83.5)	97.5 (93.8 , 99.0)	87.9 (85.8 , 89.7)	54.4 (48.2 , 60.2)			
1(a)1.1 Lymphocyte-rich	472	88.5 (83.9 , 91.9)	100.0 (- , -)	93.2 (88.8 , 96.0)	64.9 (48.6 , 77.2)			
1(a)1.2 Mixed cellularity	1,683	82.1 (79.7 , 84.2)	96.5 (91.5 , 98.6)	87.3 (84.8 , 89.4)	56.9 (49.4 , 63.7)			
1(a)1.3 Lymphocyte-depleted	178	57.5 (48.5 , 65.5)	- (- , -)	75.8 (65.2 , 83.6)	23.2 (11.8 , 36.8)			
1(a)2. Nodular sclerosis	8,493	90.6 (89.8 , 91.4)	96.7 (95.4 , 97.6)	92.9 (92.1 , 93.6)	58.2 (53.2 , 62.8)			
1(a)3. Classical Hodgkin lymphoma, NOS ^c	3,323	75.8 (73.9 , 77.6)	95.6 (91.6 , 97.7)	83.1 (81.1 , 84.8)	44.2 (39.2 , 49.1)			
1(b) Nodular lymphocyte predominant Hodgkin Lymphoma	805	95.1 (92.2 , 96.9)	100.0 (- , -)	94.9 (91.7 , 96.9)	88.0 (69.4 , 95.6)			
2 Non-Hodgkin lymphoma	156,176	68.7 (68.4 , 69.1)	88.2 (87.4 , 89.0)	75.7 (75.3 , 76.1)	60.1 (59.6 , 60.7)			
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	117	67.8 (55.4 , 77.5)	- (- , -)	77.9 (64.1 , 86.9)	44.6 (20.8 , 65.9)			
4 Lymphoid neoplasm, NOS ^c	4,176	50.0 (48.0 , 51.9)	84.6 (73.2 , 91.4)	61.9 (59.1 , 64.5)	41.0 (38.3 , 43.7)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified.

- Statistic not displayed due to less than 25 cases.

Table 9.26
All Lymphoid Neoplasms With Detailed Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Males, 2006-2012

Site	All Ages		Ages 0-19	Ages 20-64	Ages 65+
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)
Lymphoid Neoplasm	97,136	69.4 (69.0 , 69.8)	89.7 (88.8 , 90.6)	75.6 (75.2 , 76.1)	59.0 (58.2 , 59.7)
1 Hodgkin Lymphoma	8,168	85.4 (84.4 , 86.3)	96.7 (95.2 , 97.8)	88.7 (87.7 , 89.6)	54.3 (50.0 , 58.4)
1(a) Classical Hodgkin lymphoma	7,604	84.7 (83.6 , 85.7)	96.4 (94.7 , 97.5)	88.2 (87.2 , 89.2)	52.2 (47.8 , 56.4)
1(a)1. Lymphocyte-rich/mixed cellularity/ lymphocyte-depleted	1,476	83.3 (80.7 , 85.6)	98.0 (93.5 , 99.4)	87.5 (84.9 , 89.8)	55.5 (46.6 , 63.5)
1(a)1.1 Lymphocyte-rich	284	88.9 (82.8 , 92.9)	100.0 (- , -)	92.0 (85.4 , 95.7)	62.9 (40.4 , 78.9)
1(a)1.2 Mixed cellularity	1,086	84.4 (81.4 , 86.9)	97.1 (91.0 , 99.1)	87.7 (84.6 , 90.3)	58.8 (48.1 , 68.1)
1(a)1.3 Lymphocyte-depleted	106	57.6 (45.5 , 67.9)	- (- , -)	69.6 (55.1 , 80.1)	28.0 (11.6 , 47.1)
1(a)2. Nodular sclerosis	4,235	89.3 (88.0 , 90.4)	96.3 (94.3 , 97.6)	91.4 (90.1 , 92.5)	56.7 (49.2 , 63.5)
1(a)3. Classical Hodgkin lymphoma, NOS ^c	1,893	75.2 (72.7 , 77.6)	94.6 (87.6 , 97.7)	81.2 (78.6 , 83.6)	45.0 (38.0 , 51.7)
1(b) Nodular lymphocyte predominant Hodgkin Lymphoma	564	95.3 (91.6 , 97.4)	100.0 (- , -)	95.2 (91.4 , 97.3)	84.1 (57.9 , 94.7)
2 Non-Hodgkin lymphoma	86,731	68.3 (67.9 , 68.8)	88.0 (86.9 , 89.0)	74.1 (73.6 , 74.6)	59.6 (58.9 , 60.4)
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	71	77.1 (60.9 , 87.3)	- (- , -)	81.1 (64.9 , 90.3)	- (- , -)
4 Lymphoid neoplasm, NOS ^c	2,166	49.0 (46.3 , 51.6)	84.6 (69.5 , 92.6)	58.1 (54.5 , 61.6)	39.7 (35.7 , 43.7)

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified.

- Statistic not displayed due to less than 25 cases.

Table 9.27
All Lymphoid Neoplasms With Detailed Hodgkin Lymphoma Subtypes^a

SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Females, 2006-2012

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	
Lymphoid Neoplasm	78,287	70.4 (70.0 , 70.8)	90.5 (89.5 , 91.5)	79.8 (79.3 , 80.3)	59.9 (59.2 , 60.6)			
1 Hodgkin Lymphoma	6,786	87.3 (86.3 , 88.2)	97.0 (95.4 , 98.0)	92.0 (91.1 , 92.9)	54.2 (49.9 , 58.3)			
1(a) Classical Hodgkin lymphoma	6,545	87.0 (86.0 , 87.9)	96.9 (95.2 , 98.0)	92.0 (91.0 , 92.8)	52.5 (48.1 , 56.7)			
1(a)1. Lymphocyte-rich/mixed cellularity/ lymphocyte-depleted	857	78.5 (74.9 , 81.7)	96.0 (84.3 , 99.0)	88.2 (84.8 , 90.9)	53.1 (44.3 , 61.2)			
1(a)1.1 Lymphocyte-rich	188	87.9 (79.4 , 93.0)	- (- , -)	94.4 (87.9 , 97.5)	65.2 (40.6 , 81.6)			
1(a)1.2 Mixed cellularity	597	77.8 (73.4 , 81.6)	94.7 (79.9 , 98.7)	86.1 (81.6 , 89.5)	54.8 (44.1 , 64.3)			
1(a)1.3 Lymphocyte-depleted	72	56.6 (43.9 , 67.5)	- (- , -)	86.0 (69.0 , 94.1)	17.2 (6.2 , 32.8)			
1(a)2. Nodular sclerosis	4,258	92.0 (90.9 , 92.9)	97.0 (95.1 , 98.2)	94.4 (93.3 , 95.3)	59.0 (52.0 , 65.3)			
1(a)3. Classical Hodgkin lymphoma, NOS ^c	1,430	76.5 (73.7 , 79.1)	96.7 (91.3 , 98.8)	85.6 (82.6 , 88.1)	43.3 (36.1 , 50.2)			
1(b) Nodular lymphocyte predominant Hodgkin Lymphoma	241	94.5 (88.3 , 97.5)	100.0 (- , -)	93.8 (86.4 , 97.2)	91.0 (73.5 , 97.1)			
2 Non-Hodgkin lymphoma	69,445	69.3 (68.8 , 69.7)	88.6 (87.2 , 89.8)	78.0 (77.4 , 78.6)	60.7 (59.9 , 61.4)			
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	46	55.4 (36.4 , 70.9)	- (- , -)	72.3 (45.4 , 87.6)	- (- , -)			
4 Lymphoid neoplasm, NOS ^c	2,010	51.1 (48.2 , 53.9)	84.3 (61.5 , 94.1)	67.4 (63.0 , 71.4)	42.1 (38.4 , 45.7)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.


^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^c NOS = Not otherwise specified.

- Statistic not displayed due to less than 25 cases.

Figure 9.1

SEER Observed Incidence, SEER Delay Adjusted Incidence and US Death Rates^a Hodgkin Lymphoma, by Race and Sex



Source: SEER 9 areas and US Mortality Files (National Center for Health Statistics, CDC).

^a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines and APCs are calculated using the Joinpoint Regression Program Version 4.3.0.0, April 2016, National Cancer Institute.

The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.


* The APC is significantly different from zero ($p < 0.05$).

Figure 9.2

SEER Incidence and US Death Rates^a Hodgkin Lymphoma, Both Sexes

Joinpoint Analyses for Whites and Blacks from 1975-2013

and for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics from 1992-2013



Source: Incidence data for whites and blacks are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Incidence data for Asian/Pacific Islanders, American Indians/Alaska Natives and Hispanics are from the SEER 13 Areas (SEER 9 Areas, San Jose-Monterey, Los Angeles, Alaska Native Registry and Rural Georgia). Mortality data are from US Mortality Files, National Center for Health Statistics, CDC.

^a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103). Regression lines are calculated using the Joinpoint Regression Program Version 4.3.0.0, April 2016, National Cancer Institute. Joinpoint analyses for Whites and Blacks during the 1975-2013 period allow a maximum of 5 joinpoints. Analyses for other ethnic groups during the period 1992-2013 allow a maximum of 4 joinpoints.

^b API = Asian/Pacific Islander.


^c AI/AN = American Indian/Alaska Native. Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^d Joinpoint could not fit a regression line for American Indian/Alaska Native Incidence due to insufficient data.

^e Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. Mortality data for Hispanics exclude cases from New Hampshire and Oklahoma.

Figure 9.3

SEER Observed Incidence and SEER Delay Adjusted Incidence Rates^a SEER 9 Areas Compared to SEER 13 Areas Hodgkin Lymphoma, Male, by Race




● SEER 9 Delay-Adj. Incidence
 ○ SEER 9 Observed Incidence
 ■ SEER 13 Delay-Adj. Incidence
 □ SEER 13 Observed Incidence

Source: SEER 9 areas and SEER 13 areas.
^a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
 Regression lines and APCs are calculated using the Joinpoint Regression Program Version 4.3.0.0, April 2016, National Cancer Institute.
 The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.
 * The APC is significantly different from zero ($p < 0.05$).

Figure 9.4

SEER Observed Incidence and SEER Delay Adjusted Incidence Rates^a SEER 9 Areas Compared to SEER 13 Areas Hodgkin Lymphoma, Female, by Race



● SEER 9 Delay-Adj. Incidence
 ○ SEER 9 Observed Incidence
 ■ SEER 13 Delay-Adj. Incidence
 □ SEER 13 Observed Incidence


Source: SEER 9 areas and SEER 13 areas.
^a Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).
 Regression lines and APCs are calculated using the Joinpoint Regression Program Version 4.3.0.0, April 2016, National Cancer Institute.
 The APC is the Annual Percent Change for the regression line segments. The APC shown on the graph is for the most recent trend.
 * The APC is significantly different from zero ($p < 0.05$).

Figure 9.5

Hodgkin Lymphoma

5-Year SEER Conditional Relative Survival and 95% Confidence Intervals

Probability of surviving the next 5 years given the cohort
has already survived 0, 1, or 3 years
1998-2012 by stage at diagnosis



Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG contribute cases for diagnosis years 2000 and later. The remaining 13 SEER Areas contribute cases for the entire time period. Percent surviving is not shown if based on less than 25 cases. Confidence intervals are not shown if length of the confidence interval is greater than 5 times the standard error.